Phosphohistone H3 (pHH3) is a prognostic and epithelial to mesenchymal transition marker in diffuse gliomas.
The World Health Organization (WHO) grading of gliomas stratifies tumors by histology. However, the aggressiveness of tumors in each grade still shows great heterogeneity. Phosphohistone H3 (pHH3) has been reported as an accurate marker of cells within the mitotic phase of the cell cycle in many kinds of cancers. To evaluate the role of pHH3 in predicting patient outcome and to annotate the functions of pHH3 in WHO grade II-IV gliomas, we analyzed the expression pattern of pHH3 and pHH3 associated genes by IHC and mRNA expression profiling. Phosphohistone H3, mRNA enrichment of histone H3 and associated gene signature all showed prognostic value in adult diffuse gliomas. Gene set enrichment analysis suggested that the expression of pHH3 had positive correlation with both epithelial to mesenchymal transition and immune response. These findings suggest that subgroups of diffuse gliomas defined by pHH3 and pHH3 signatures possess distinctive prognostic and biological characteristics.
Department of Otolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Ping
P
Zhu
Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China.|Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.|Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing 100069, China.|China National Clinical Research Center for Neurological Diseases, Beijing 100050, China.
Chuan-Bao
CB
Zhang
Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China.|Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.|Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing 100069, China.|China National Clinical Research Center for Neurological Diseases, Beijing 100050, China.
Pei
P
Yang
Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China.
Jing
J
Chen
Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China.
Yu-Qing
YQ
Liu
Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China.
Hui-Min
HM
Hu
Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China.
Hua
H
Huang
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.|China National Clinical Research Center for Neurological Diseases, Beijing 100050, China.
Zhao-Shi
ZS
Bao
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.|China National Clinical Research Center for Neurological Diseases, Beijing 100050, China.
Wei
W
Zhang
Department of Otolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Wei-Jia
WJ
Kong
Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China.|Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.|Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing 100069, China.|China National Clinical Research Center for Neurological Diseases, Beijing 100050, China.
Tao
T
Jiang
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology*; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D020869:Gene Expression Profiling; D005910:Glioma / Q000401:mortality / Q000473:pathology*; D006657:Histones / Q000032:analysis / Q000096:biosynthesis*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D010766:Phosphorylation; D011379:Prognosis; D016016:Proportional Hazards Models; D059467:Transcriptome
D014408:Biomarkers, Tumor; D006657:Histones
EMT; glioma; pHH3; prognosis